DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
DYADIC INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.03 (-7.35%)
Close on Oct 19, 2026
- Market cap
- $13.88M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.6891 (−64.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
DYADIC INTERNATIONAL INC saw revenue fall 8.0% to $3.80M over the twelve months to Jun 30, 2026.
Revenue
$3.80M
-8.0% vs. a year earlier
Operating income
-$7.42M
TTM Q2 2026
EPS, diluted
-$0.23
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $13.88M
- P/E ratio
- –
- Price to sales
- 3.65
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.80M
- Net income
- -$7.62M
- EPS, diluted
- -$0.23
- Book value per share
- -$0.07
- Diluted shares
- 36M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$3.80M-8.0% YoY
Gross profit
$617.62K-75.0% YoY
Operating income
-$7.42M
Net income
-$7.62M
EPS, diluted
-$0.23
Reported periodTrailing twelve months